Waiv will apply its computational pathology platform to support biomarker discovery in an undisclosed antibody-drug conjugate (ADC) program at Daiichi Sankyo (TSE: 4568), the companies announced. The Paris-based Waiv, formerly operating as Owkin Dx, will lead digital pathology analysis using artificial intelligence to identify biomarkers of treatment response ahead of future clinical trial phases.
Under the agreement, Waiv will deploy its end-to-end computational pathology platform against early-phase program data provided by Daiichi Sankyo. The work encompasses tumor microenvironment analysis across both hematoxylin and eosin and immunohistochemistry stained samples, alongside biomarker discovery and outcome prediction workflows. The platform is designed to operate in data-constrained settings, with Waiv noting the approach is built to extract predictive signals from fewer than approximately 100 patients — a common constraint in early oncology programs. The platform is trained on large-scale pathology image datasets sourced from academic and clinical partners from Waiv’s international data network. The platform generates histopathological biomarker candidates beyond predefined features and produces outputs characterized as reproducible and interpretable for potential clinical application.
Neither financials nor details on the ADC’s target, indication, development code, or associated clinical trials were disclosed.
Daiichi Sankyo has built one of the more active ADC portfolios in oncology over the past several years, with programs spanning multiple tumor types and a series of high-value partnerships with larger pharmaceutical companies. The current collaboration follows a similar agreement between Tempus AI and Daiichi Sankyo announced in March, under which Tempus applied its AI and real-world data platform to biomarker discovery and patient stratification for an undisclosed ADC program. Unlike Tempus’s multimodal approach combining clinical, genomic, and real-world data, Waiv’s platform is centered on computational pathology and image-derived biomarkers. Waiv, formerly the diagnostics arm of Owkin, operates within a cohort of AI pathology firms targeting oncology drug development.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/